[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342617-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342617-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","top2a-modulates-signaling-via-the-aktmtor-pathway-to-promote-ovarian-cancer-cell-proliferation-research-paper","TOP2A modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation - Research Paper","","Ovarian cancer remains a highly lethal gynecological malignancy, with outcomes worse than other female reproductive tract cancers. This study investigates TOP2A as a driver of ovarian cancer progression by integrating online database analysis, clinical samples, and in vitro/in vivo experiments. TOP2A expression is elevated in tumors and associates with poorer prognosis, while TOP2A knockdown suppresses proliferation, induces G1 arrest, and promotes apoptosis. Rescue assays demonstrate that TOP2A regulates proliferation and cell-cycle progression through AKT/mTOR pathway activity, with mouse models confirming its role in tumor growth.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/top2a-modulates-signaling-via-the-aktmtor-pathway-to-promote-ovarian-cancer-cell-proliferation-research-paper/342617/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/top2a-modulates-signaling-via-the-aktmtor-pathway-to-promote-ovarian-cancer-cell-proliferation-research-paper/342617.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How is TOP2A related to prognosis in ovarian cancer patients?","Question",{"text":63,"@type":64},"Higher TOP2A expression is observed in ovarian cancer tissues compared with healthy tissue and is correlated with worse prognosis in Kaplan-Meier analyses.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What happens to ovarian cancer cells when TOP2A is knocked down?",{"text":68,"@type":64},"TOP2A knockdown inhibits cell proliferation, causes G1 phase arrest, and leads to apoptotic cell death.",{"name":70,"@type":61,"acceptedAnswer":71},"Which pathway mediates TOP2A’s effects on cell proliferation and the cell cycle?",{"text":72,"@type":64},"Rescue assays indicate that TOP2A regulates proliferation and cell-cycle progression via AKT/mTOR pathway activity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342617,1790472790,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":26,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","CANCER BIOLOGY & THERAPY  \n2024, VOL. 25, NO. 1, 2325126 [https://doi.org/10.1080/15384047.2024.2325126](https://doi.org/10.1080/15384047.2024.2325126)  \nRESEARCH PAPER  \nTOP2A modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation  \nKaiwen Zhanga*, Xingyu Zhenga*, Yiqing Suna*, Xinyu Fenga, Xirong Wub, Wenlu Liua, Chao Gaoa, Ye Yana, Wenyan Tiana, and Yingmei Wang a  \naDepartment of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China; bDepartment of Gynecology and Obstetrics, Affiliated Hospital of Nantong University, Nantong, China  \nABSTRACT  \nOvarian cancer (OC) is a form of gynecological malignancy that is associated with worse patient outcomes than any other cancer of the female reproductive tract. Topoisomerase II α (TOP2A) is commonly regarded as an oncogene that is associated with malignant disease progression in a variety of cancers, its mechanistic functions in OC have yet to be firmly established. We explored the role of TOP2A in OC through online databases, clinical samples, in vitro and in vivo experiments. And initial analyses of public databases revealed high OC-related TOP2A expression in patient samples that was related to poorer prognosis. This was confirmed by clinical samples in which TOP2A expression was elevated in OC relative to healthy tissue. Kaplan-Meier analyses further suggested that higher TOP2A expression levels were correlated with worse prognosis in OC patients. In vitro, TOP2A knockdown resulted in the inhibition of OC cell proliferation, with cells entering G1 phase arrest and undergoing consequent apoptotic death. In rescue assays, TOP2A was confirmed to regulate cell proliferation and cell cycle through AKT/mTOR pathway activity. Mouse model experiments further affirmed the key role that TOP2A plays as a driver of OC cell proliferation. These data provide strong evidence supporting TOP2A as an oncogenic mediator and prognostic biomarker related to OC progression and poor outcomes. At the mechanistic level, TOP2A can control tumor cell growth via AKT/mTOR pathway modulation. These preliminary results provide a foundation for future research seeking to explore the utility of TOP2A inhibitor-based combination treatment regimens in platinum-resistant recurrent OC patients.  \nARTICLE HISTORY  \nReceived 6 October 2023 Revised 24 February 2024 Accepted 26 February 2024  \nKEYWORDS  \nOvarian cancer; TOP2A; prognosis; proliferation; rescue experiments; AKT/ mTOR signaling pathway  \nIntroduction  \nOvarian cancer (OC) is the deadliest form of gynecological malignancy, posing a significant threat to the health of women throughout the globe. In 2020 alone, there were an estimated 313,959 OC diagnoses and 207,252 deaths among affected patients. 1 In the USA alone, the American Cancer Society predicts that there will be 19,710 cases of OC diagnosed in the USA in 2023, with 13,270 deaths.2 While OC is not the most commonly diagnosed cancer of the female reproductive tract, its incidence continues to rise annually. Pathological subtypes of OC include epithelial OC, which is dominant and accounts for > 90% of cases,3 while high-grade serous OC is the most frequently diagnosed histological subtype, comprising approximately 75% of all epithelial OC cases.4  \nIn its early stages, the symptoms of OC are relatively nonspecific such that an estimated 75% of patients are only diagnosed when the disease is relatively advanced, with a 5-year survival rate of just 29–48% . In patients with platinumresistant recurrent disease, the survival duration is only 12–14 months on average.4,5 As such, there remains a pressing need to design new strategies capable of improving survival outcomes in platinum-resistant patients with recurrent disease.  \nIn patients with platinum-resistant disease, non-platinum drugs are the primary therapeutic approach, including weekly treatment with paclitaxel, docetaxel, the topoisomerase (TOP) IIα inhibitor etoposide, TOP IIβ ","cbCaiqNc5GFzxRMf","https://ap.wps.com/l/cbCaiqNc5GFzxRMf","pdf",8322252,16,"English","# Abstract\n# Introduction\n## Epidemiology and clinical need\n## Current therapies for platinum-resistant disease\n## TOP enzymes and biological rationale","[{\"question\":\"How is TOP2A related to prognosis in ovarian cancer patients?\",\"answer\":\"Higher TOP2A expression is observed in ovarian cancer tissues compared with healthy tissue and is correlated with worse prognosis in Kaplan-Meier analyses.\"},{\"question\":\"What happens to ovarian cancer cells when TOP2A is knocked down?\",\"answer\":\"TOP2A knockdown inhibits cell proliferation, causes G1 phase arrest, and leads to apoptotic cell death.\"},{\"question\":\"Which pathway mediates TOP2A’s effects on cell proliferation and the cell cycle?\",\"answer\":\"Rescue assays indicate that TOP2A regulates proliferation and cell-cycle progression via AKT/mTOR pathway activity.\"}]","TOP2A modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation - Research Paper | PDF",1790047421,[146,150],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/c7f608fe027d0ae0789ee7552f69e65c.webp",983,1280,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/a6e2a75428624a553387e67cb6d385f5.webp",982,1279]